This application is a continuation-in-part of U.S. patent application Ser. No. 08/718,703, filed Sep. 27, 1996, now U.S. Pat. No. 5,824,662; U.S. patent application Ser. No. 08/775,586, filed Dec. 31, 1996, now U.S. Pat. No. 5,795,877; U.S. patent application Ser. No. 08/778,733, filed Dec. 31, 1996, now U.S. Pat. No. 5,863,536; U.S. patent application Ser. No. 08/825,997, filed Apr. 4, 1997; U.S. patent application Ser. No. 08/835,572, filed Apr. 9, 1997; U.S. patent application Ser. No. 08/842,360, filed Apr. 24, 1997; U.S. patent application Ser. No. 08/863,624, filed May 27, 1997; U.S. patent application Ser. No. 08/858,985, filed May 27, 1997; and U.S. patent application Ser. No. 08/884,479, filed Jun. 27, 1997, which in turn is a continuation-in-part of U.S. patent application Ser. No. 08/718,703, filed Sep. 27, 1996, now U.S. Pat. No. 5,824,662; the entire contents of which applications are herein incorporated by reference.
Compounds of the following formula (I), for example: (1), wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein. ##STR00001##
The present invention relates to chemical compounds comprising a nitric oxide (NO) donor and a superoxide ion (O.sub.2.sup.-) scavenger, their preparation and their use in the treatment of conditions associated with oxidative stress or endothelial dysfunction. In particular, the present invention relates to chemical compounds of Formula (I) wherein: R.sup.1 may be the same of different and are independently selected from hydrogen, alkoyl, carboxy, hydroxy, amino, amido, cyano, nitro, thio, sulphonyl, sulphoxide alkyl groups comprising an NO-donor, provided that at least one R.sup.1 is a group comprising an NO-donor; R.sup.2 may be the same or different and are independently selected from alkyl groups; n is an integer 1, 2, or 3; or a salt thereof.
The present invention relates to pharmaceutical compositions and methods of using pyrrolecarbonylimino derivatives to inhibit N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity, thereby effecting neuronal activities, inhibiting angiogenesis, and treating glutamate abnormalities, compulsive disorders, prostate diseases and cancers.
Administration of .beta.-lactam compounds including .beta.-lactam antibiotics and .beta.-lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior modification and enhanced cognition. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.
Administration of clavulanic acid and related compounds at low dosages provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior and enhanced cognition believed to be mediated by inhibition of neurogenic enzyme activity. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.
